NCT03420300View on ClinicalTrials.gov

EBR/GZR for HCV-1b Patients Receiving Hemodialysis

PHASE4CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

June 5, 2018

Primary Completion Date

November 2, 2019

Study Completion Date

February 3, 2020

Conditions
Hepatitis C
Interventions
DRUG

EBR/GZR

Elbasvir/grazoprevir (EBR/GZR 50mg/100mg fixed dose combination \[FDC\]): 1 table per os per day for 12 weeks

Trial Locations (6)

Unknown

National Taiwan University Hospital, Yun-Lin Branch, Douliu

China Medical University Hospital, Taichung

Taichung Veterans General Hospital, Taichung

National Taiwan University Hospital, Taipei

Taipei Medical University, Taipei

Far Eastern Memorial Hospital, Taipei County

All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

National Taiwan University Hospital

OTHER

NCT03420300 - EBR/GZR for HCV-1b Patients Receiving Hemodialysis | Biotech Hunter | Biotech Hunter